Psoriatic Arthritis

Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

By

Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.

High-Intensity Interval Training Has No Effect on Disease Activity in Psoriatic Arthritis

High-Intensity Interval Training Has No Effect on Disease Activity in Psoriatic Arthritis

By

High-intensity interval training showed no clear effects on disease activity markers in patients with psoriatic arthritis.

Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

By

Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.

TNFi More Effective in Men vs Women With Psoriatic Arthritis

TNFi More Effective in Men vs Women With Psoriatic Arthritis

By

Male gender was associated with better biologic treatment effectiveness in psoriatic arthritis.

ABT-122 Shows Similar Safety, Efficacy to Adalimumab in Psoriatic Arthritis

ABT-122 Shows Similar Safety, Efficacy to Adalimumab in Psoriatic Arthritis

By

ABT-122 demonstrated efficacy and safety similar to adalimumab over 12 weeks in patients with psoriatic arthritis who had an inadequate response to methotrexate.

FDA: Secukinumab Slows Progression of Joint Structural Damage in Psoriatic Arthritis

FDA: Secukinumab Slows Progression of Joint Structural Damage in Psoriatic Arthritis

By

The FDA has approved updated labeling for Cosentyx that includes data demonstrating that the drug slows the progression of joint structural damage in patients with active psoriatic arthritis.

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

By

It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

By

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

By

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

By

Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

By

The outcome measure may be considered a practical alternative to the Psoriasis Area and Severity Index for the measurement of psoriasis severity and response to therapy.

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

By

The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.

Hitting the Target in Psoriatic Arthritis: Which Outcome Measures Are Best?

Hitting the Target in Psoriatic Arthritis: Which Outcome Measures Are Best?

By

Experts are still debating the utility of a unidimensional composite score compared with a multidimensional score for the assessment of disease activity in psoriatic arthritis.

Low Conversion Rate of Quantiferon-TB Test in TNF Inhibitor-Treated Patients

Low Conversion Rate of Quantiferon-TB Test in TNF Inhibitor-Treated Patients

By

Investigators sought to determine the rate of conversion of Quantiferon-TB Gold screening test in patients taking anti-TNF therapy.

Power Doppler Ultrasound Abnormalities Evaluated in Psoriatic Arthritis

Power Doppler Ultrasound Abnormalities Evaluated in Psoriatic Arthritis

By

Researchers sought to evaluate the prevalence rates of peripheral joint, enthesis, tendon, and bursa abnormalities by power Doppler ultrasound in patients with psoriatic arthritis and patients with psoriasis without clinical signs of arthritis.

Incidence of Cardiovascular Events Similar in Rheumatoid Arthritis, Spondyloarthritis

Incidence of Cardiovascular Events Similar in Rheumatoid Arthritis, Spondyloarthritis

By

The incidence of adverse cardiovascular events in patients with RA do not differ significantly compared with those with PsA or axSpA.

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

By

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

By

Researchers aimed to compare the disease burden of patients with psoriatic arthritis with low disease activity according to 2 definitions.

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

By

Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

By

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

By

The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

By

Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

By

The results of the FUTURE 5 study show that secukinumab improved signs and symptoms and inhibited radiographic structural progression at 24 weeks in psoriatic arthritis.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

By

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

By

Dual inhibition of IL-17A and IL-17F with bimekizumab suppresses joint inflammation in patients with psoriatic arthritis.

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

By

The accessory pulleys linked to the flexor tendons are thicker in patients with psoriatic arthritis.

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

By

The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

By

Initial response to psoriatic arthritis therapy has a predictive value of long-term outcomes as early as 3 months after treatment initiation.

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

By

Results from the FUTURE 2 study show that patients with PsA who were treated with secukinumab achieved early and sustained minimal disease activity over 2 years of therapy.

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

By

Psoriatic arthritis is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease.

Sign Up for Free e-newsletters